Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1B/2A Trial of CEND-1 in Combination with Neoadjuvant FOLFIRINOX Based Therapies in Pancreatic, Colon and Appendiceal Cancers (CENDIFOX)

NCT05121038 is registered in ClinicalTrials.gov with Anup Kasi as lead sponsor.

NCT NCT05121038
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05121038 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1B/2A Trial of CEND-1 in Combination with Neoadjuvant FOLFIRINOX Based Therapies in Pancreatic, Colon and Appendiceal Cancers (CENDIFOX)
Lead sponsor
Anup Kasi
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
October 20, 2021
Completion date
September 30, 2026
Enrollment
50 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

colon cancer, digestive cancer, pancreas cancer